蛋白质组学分析识别外周T细胞淋巴瘤非特指型患者结局预测标志物
研究采用蛋白质组学分析治疗前外周T细胞淋巴瘤非特指型(PTCL-NOS)肿瘤的蛋白表达,比较肿瘤与良性淋巴组织、主成分分析(PCA)定义的聚类及化疗敏感与难治肿瘤间的差异蛋白。在87例PTCL-NOS患者中经免疫组化验证,α-烯醇化酶1(ENO1)高表达与不良结局相关(HR 2.09,95%CI 1.17-3.73,P=0.013)。
要点
- PTCL-NOS肿瘤与良性淋巴组织间多数蛋白表达存在差异。
- PCA将PTCL-NOS分为2个总生存率不同的聚类(P=0.001)。
- 免疫组化显示ENO1高表达与不良结局相关(HR 2.09,P=0.013)。
核心结论
- PTCL-NOS蛋白质组学分析提供了蛋白表达显著改变的证据,并识别ENO1为新的潜在预后标志物。
研究设计与样本
- 研究采用蛋白质组学分析治疗前PTCL-NOS肿瘤的蛋白表达,比较PTCL-NOS肿瘤组织(n=18)与良性淋巴组织(n=8)、PCA定义的聚类以及化疗敏感与难治PTCL-NOS患者的肿瘤。
- 在较大队列PTCL-NOS患者(n=87)中,通过免疫组化(IHC)将蛋白质组学识别的差异表达蛋白与临床病理特征和结局进行关联。
主要发现
- 大多数表达改变的蛋白通过比较PTCL-NOS与良性淋巴组织识别。
- PCA定义了3个不同的蛋白谱聚类,所有良性样本聚类在一起,而PTCL-NOS肿瘤分为2个聚类,患者总生存率不同(P=0.001)。
- 差异表达蛋白反映PTCL-NOS较大的生物学多样性,尤其与「免疫」通路改变相关;PCA定义的2个PTCL-NOS亚聚类显示「应激相关」和「蛋白代谢」通路紊乱。
- α-烯醇化酶1(ENO1)在所有3项分析中均差异表达,IHC评估的高瘤内ENO1表达与不良结局相关(风险比2.09;95%置信区间1.17-3.73;P=0.013)。
- 磷酸丙糖异构酶(TPI1)高表达也显示与不良生存相关的趋势(P=0.057)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) constitutes a heterogeneous category of lymphomas, which do not fit into any of the specifically defined T-cell lymphoma entities. Both the pathogenesis and tumor biology in PTCL-NOS are poorly understood. Protein expression in pretherapeutic PTCL-NOS tumors was analyzed by proteomics. Differentially expressed proteins were compared in 3 distinct scenarios: (A) PTCL-NOS tumor tissue (n = 18) vs benign lymphoid tissue (n = 8), (B) clusters defined by principal component analysis (PCA), and (C) tumors from patients with chemosensitive vs refractory PTCL-NOS. Selected differentially expressed proteins identified by proteomics were correlated with clinico-pathological features and outcome in a larger cohort of patients with PTCL-NOS (n = 87) by immunohistochemistry (IHC). Most proteins with altered expression were identified comparing PTCL-NOS vs benign lymphoid tissue. PCA of the protein profile defined 3 distinct clusters. All benign samples clustered together, whereas PTCL-NOS tumors separated into 2 clusters with different patient overall survival rates (P = .001). Differentially expressed proteins reflected large biological diversity among PTCL-NOS, particularly associated with alterations of "immunological" pathways. The 2 PTCL-NOS subclusters defined by PCA showed disturbance of "stress-related" and "protein metabolic" pathways. α-Enolase 1 (ENO1) was found differentially expressed in all 3 analyses, and high intratumoral ENO1 expression evaluated by IHC correlated with poor outcome (hazard ratio, 2.09; 95% confidence interval, 1.17-3.73; P = .013). High expression of triosephosphate isomerase (TPI1) also showed a tendency to correlate with poor survival (P = .057). In conclusion, proteomic profiling of PTCL-NOS provided evidence of markedly altered protein expression and identified ENO1 as a novel potential prognostic marker.
引用
- Ludvigsen M, Bjerregård Pedersen M, Lystlund Lauridsen K, et al. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. Blood Adv. 2018. PMID: 30291111. doi:10.1182/bloodadvances.2018019893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。